Health fair screening: The clinical utility of the comprehensive metabolic profile

Family Medicine

Volumn 36, Issue 7, 2004, Pages 514-519

  Alpert, Jeffrey P ^a   Greiner, K Allen ^b,c   Hall, Sandra ^c  

^a Wichita County Health Center   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; BLOOD SAMPLING; CAUCASIAN; CONFERENCE PAPER; DEMOGRAPHY; DIAGNOSTIC VALUE; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CARE ORGANIZATION; HEALTH CARE UTILIZATION; HEALTH CENTER; HEALTH EDUCATION; HISPANIC; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL RECORD; METABOLIC PARAMETERS; PHYSICIAN; POPULATION; PREDICTION; PREDICTION AND FORECASTING; RESIDENT; REVIEW; RURAL AREA; SCREENING TEST;

ADULT; BILIRUBIN; BLOOD CHEMICAL ANALYSIS; HEALTH FAIRS; HUMANS; LIVER FUNCTION TESTS; MASS SCREENING; METABOLIC DISEASES; PHYSICAL EXAMINATION; PREDICTIVE VALUE OF TESTS; PUBLIC HEALTH; RURAL HEALTH;

EID: 3142686700     PISSN: 07423225     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Berwick DM. Screening in health fairs. A critical review of benefits, risks, and costs. JAMA 1985;254:1492-8.
2. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin 2003;53:27-43.
3. US Preventive Services Task Force. Guide to clinical preventive services, third edition, periodic updates. Report of the US Preventive Services Task Force. USPSTF methods.www.ahrq.gov/clinic/uspstfix.htm. Accessed March 6, 2004.
4. American Academy of Family Physicians. Clinical care and research. Periodic health examinations.www.aafp.org/exam.xml. Accessed March 6, 2004.
5. US Preventive Services Task Force. www.ahrq.gov/clinic/uspstfix.htm. Accessed December 3, 2003.
6. American Heart Association. www.ahascienceonline.org/atp/index.asp?sid=1. Accessed December 3, 2003.
7. American Diabetes Association. http://diabetes.org/professional/cpr_home. jsp. Accessed December 3, 2003.
8. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001;20:21-35.
9. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending. Part 1: the content, quality, and accessibility of care. Ann Intern Med 2003;138:273-87.
10. Wennberg DE, Kellett MA, Dickens JD, Malenka DJ, Keilson LM, Keller RB. The association between local diagnostic testing intensity and invasive cardiac procedures. JAMA 1996;275:1161-4.
11. American College of Physicians. www.acponline.org/sci-policy/guidelines/? hp. Accessed December 3, 2003.
12. US Census Bureau. http://quickfacts.census.gov/qfd/states/20/20203.html. Accessed December 9, 2003.
13. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
14. Mayfield J. Diagnosis and classification of diabetes mellitus: new criteria. Am Fam Physician 1998;58(6):1355-62.
15. US Preventive Services Task Force. Update, 2003 release. www.ahcpr.gov/clinic/uspstf/uspsdiab.htm. Accessed 2-10-2004.
16. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
17. Jorde R, Bonaa KH, Sundsfjord J. Primary hyperparathyroidism detected in a health screening. The Tromso study. J Clin Epidemiol 2000;53(11):1164-9.
18. Lundgren E, Rastad J, Thrufjell E, Akerstrom G, Ljunghall S. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 1997;121(3):287-94.
19. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2)Suppl 1(Feb):S46-S110.
20. www.kidney.org/professionals/doqi/index.cfm. Accessed 2-10-2004.
21. Iseki K, Ikemiya Y, Fukiyama K. Risk factors of end-stage renal disease and serum creatinine in a community-based mass screening. Kidney Int 1997;51:850-4.
22. Duncan L, Heathcote J, Djurdjev O, Levin A. Screening for renal disease using serum creatinine: who are we missing?. Nephrol Dial Transplant 2001;16:1042-6.
23. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000;342:1266-71.
24. Mathiesen UL, Franzen LE, Fryden A, Foberg U, Bodemar G. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol 1999;34:85-91.
25. Younossi ZM. Evaluating asymptomatic patients with mildly elevated liver enzymes. Cleve Clin J Med 1998;65:150-8.
26. Johnston DE. Special considerations in interpreting liver function tests. Am Fam Physician 1999;59(8):2223-32.
27. Aertgeerts B, Buntinx F, Ansoms S, Fevery J. Screening properties of questionnaires and laboratory tests for the detection of alcohol abuse or dependence in a general practice population. Br J Gen Pract 2001;51(464):206-17.
28. Yano E, Tagawa K, Yamaoka K, Mori M. Test validity of periodic liver function tests in a population of Japanese male bank employees. J Clin Epidemiol 2001;54(9):945-51.
29. Takemura Y, Ishida H, Inoue Y, Kobayashi H, Beck JR. Opportunistic discovery of occult disease by use of test panels in new, symptomatic primary care outpatients: yield and cost of case finding. Clin Chem 2000;46(8):1091-8.